Pathophysiology and Therapeutic Interventions in Diabetic Nephropathy

Diabetic nephropathy arises from chronic hyperglycaemia-induced damage to the renal microvasculature, manifesting initially as glomerular hyperfiltration and microalbuminuria. Persistent metabolic stress triggers oxidative stress, accumulation of advanced glycation end products, and activation of pro-inflammatory and profibrotic signalling pathways such as transforming growth factor-β and nuclear factor-κB. Podocyte injury, endothelial dysfunction and mesangial expansion converge to impair the glomerular filtration barrier, progressing to overt proteinuria, renal fibrosis and eventual loss of function. Current standard care comprises strict glycaemic and blood pressure control, renin–angiotensin–aldosterone system blockade and lifestyle modification. Recent advances have extended beyond blockade of haemodynamic stress to therapies targeting metabolic pathways and cellular homeostasis, including sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists. Emerging strategies focus on modulation of oxidative stress, autophagy regulation, inhibition of epithelial-to-mesenchymal transition and novel cell-based approaches to attenuate fibrosis and promote repair.

Research from Nature Portfolio

Studies have elucidated the importance of endoplasmic reticulum stress and autophagy in podocyte survival. One investigation demonstrated that restoring sarco/endoplasmic reticulum Ca²⁺-ATPase function alleviates endoplasmic reticulum stress and prevents podocyte apoptosis, thereby slowing albuminuria and glomerulosclerosis in experimental diabetic models. Another report revealed that enhancing autophagy via the Sirtuin-1–nuclear factor-κB axis inhibits glucose-induced epithelial-to-mesenchymal transition in podocytes, reducing fibrotic change and improving renal function. Together, these works underscore the therapeutic potential of targeting intracellular quality-control mechanisms to preserve glomerular integrity in diabetic nephropathy.

Pathophysiology and Therapeutic Interventions in Diabetic Nephropathy publication trend

The graph below shows the total number of articles in pathophysiology and therapeutic interventions in diabetic nephropathy across all publications each year (not limited to Nature Index journals).

Technical terms

Glomerular hyperfiltration: Elevated glomerular filtration rate in early diabetes that contributes to subsequent renal injury.

Podocyte: Specialized epithelial cell in the glomerulus essential for filtration barrier integrity.

Autophagy: Intracellular degradation process that removes damaged organelles and proteins to maintain cellular homeostasis.

Epithelial-to-mesenchymal transition (EMT): Biological process by which epithelial cells acquire a fibrogenic, mesenchymal phenotype.

Advanced glycation end products (AGEs): Proteins or lipids modified by sugars that promote inflammation and fibrosis.

Sodium–glucose cotransporter 2 (SGLT2) inhibitor: Class of antihyperglycaemic agent that reduces renal glucose reabsorption, offering nephroprotection.

References

1. Astragaloside IV Attenuates Podocyte Apoptosis Mediated by Endoplasmic Reticulum Stress through Upregulating Sarco/Endoplasmic Reticulum Ca2+-ATPase 2 Expression in Diabetic Nephropathy. Frontiers in Pharmacology (2016).
2. Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT–NF-κB p65 axis. Scientific Reports (2019).
3. Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention. Renal Failure (2023).
4. Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF-κB signaling pathway in vivo and in vitro. Stem Cell Research & Therapy (2018).
5. Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network. PLOS ONE (2017).